News

Article

China’s NMPA Accepts sNDA for Penpulimab Plus Anlotinib for Advanced HCC

Author(s):

Fact checked by:

China's NMPA has accepted a sNDA for penpulimab plus anlotinib for the first-line treatment of advanced hepatocellular carcinoma.

Penpulimab Plus Anlotinib for Advanced HCC | Image Credit: © Sebastian Kaulitzki - stock.adobe.com

Penpulimab Plus Anlotinib for Advanced

HCC | Image Credit: © Sebastian Kaulitzki

- stock.adobe.com

China's National Medical Products Administration (NMPA) has accepted a supplemental new drug application (sNDA) seeking the approval of penpulimab (formerly AK105) in combination with anlotinib (AL3818) for the first-line treatment of patients with advanced hepatocellular carcinoma (HCC).1

The sNDA is supported by data from the phase 3 APOLLO/ALTN-AK105-III-02 study (NCT04344158). Findings from the multicenter, randomized, open-label, parallel-controlled trial shared at the 2024 ESMO Congress demonstrated that patients treated with anlotinib plus penpulimab (n = 433) experienced a median progression-free survival (PFS) of 6.9 months (95% CI, 5.7-8.0) compared with 2.8 months (95% CI, 2.7-4.1) for those given sorafenib (Nexavar) monotherapy (n = 216; HR, 0.53; 96% CI, 0.41-0.68; P < .0001).2

The median overall survival (OS) was 16.5 months (95% CI, 14.7-19.7) vs 13.2 months (95% CI, 9.7-16.9) for penpulimab plus anlotinib and sorafenib, respectively (HR, 0.69; 98.8% CI, 0.52-0.92; P = .0012).

Investigators enrolled patients with histologically confirmed HCC who were classified as Child-Pugh class A or B (≤ 7). Eligible patients also needed to have Barcelona Clinic Liver Cancer stage B (unsuitable for radical surgery and/or locoregional treatment) or C disease; an ECOG performance status of 0 or 1; and at least 1 measurable lesion per RECIST 1.1 criteria. No prior systemic therapy was permitted.

Investigators randomly assigned patients 2:1 to receive oral anlotinib at 10 mg once per day on days 1 through 14 of each 21-day cycle and 200 mg of intravenous penpulimab once every 3 weeks; or oral sorafenib at 400 mg twice per day.

The trial’s dual primary end points included PFS per independent review committee assessment and OS; secondary end points were PFS by investigator assessment, overall response rate, disease control rate, duration of response, and safety/tolerability.

Regarding safety, the combination was tolerable and manageable. The median duration of exposure for both anlotinib and penpulimab was 10.0 cycles (interquartile range [IQR], 4.0-16.0), and the median duration of exposure was 4.0 cycles (IQR, 2.0-8.0) for sorafenib. Any-grade treatment-emergent adverse effects (TEAEs) were reported in 98.8% of patients in the combination arm vs 98.6% of patients in the control arm; the rates of grade 3 or higher TEAEs were 58.6% and 54.5%, respectively.

Treatment-related AEs (TRAEs) occurred in 96.5% of patients in the experimental arm and 94.8% of patients in the control arm; the respective rates of grade 3 or higher TRAEs were 48.2% and 47.4%. The rates of serious TRAEs were 20.4% for the combination and 9.0% for sorafenib.

TEAEs led to dose reductions of anlotinib in 16.2% of patients and sorafenib in 29.9% of patients. TEAEs led to dose interruptions of penpulimab in 34.0% of patients, anlotinib in 43.8% of patients, and sorafenib in 38.9% of patients. The rates of TEAEs leading to treatment discontinuation were 6.7% for both anlotinib and penpulimab compared with 4.3% for sorafenib.

The most common any-grade TRAEs reported in at least 20% of patients included hypertension (penpulimab/anlotinib, 44.0%; sorafenib, 37.4%), decreased platelet count (37.5%; 32.2%), increased aspartate aminotransferase level (34.5%; 34.6%), increased blood bilirubin level (31.0%; 28.0%), decreased white blood cell count (27.8%; 18.5%), increased alanine aminotransferase level (27.3%; 22.8%), decreased neutrophil count (19.0%; 12.3%), and palmar-plantar erythrodysesthesia (18.8%; 32.2%).

Per investigator assessment, any-grade immune-mediated AEs reported in the anlotinib plus penpulimab arm included pneumonitis (0.9%), enterocolitis (0.5%), hepatitis (0.5%), hypothyroidism (0.2%), myositis (0.2%), and neuropathy (0.2%). No instances of immune-mediated myocarditis were reported.

References

  1. Akeso's penpulimab combination therapy for first-line treatment of hepatocellular carcinoma accepted by NMPA. Akeso. News release. November 22, 2024. Accessed November 25, 2024. https://akesobio.com/en/media/akeso-news/akesos-penpulimab-combination-therapy-for-first-line-treatment-of-hepatocellular-carcinoma-accepted-by-nmpa/
  2. Zhou J, Fan J, Jiao S, et al. Primary results from the phase III ALTN-AK105-III-02 study: Anlotinib plus penpulimab versus sorafenib as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC). Ann Oncol. 2024;35(suppl 2):S1231. doi:10.1016/j.annonc.2024.08.2280
Related Videos
Rena Callahan, MD, and Chandler Park, MD, FACP
Prithviraj Bose, MD, and Chandler Park, MD, FACP
Eunice Wang, MD, and Chandler Park, MD, FACP
Yelena Y. Janjigian, MD, chief, Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center
Richard Kim, MD, Moffitt Cancer Center
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.
Tanios Bekaii-Saab, MD, FACP